Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors
Tuesday, October 12, 2010 - 11:31
in Health & Medicine
The results of a large Phase-III clinical trial have shown that the drug everolimus delays tumor progression in patients with a hard-to-treat group of rare cancers that affect particular hormone-producing cells.